This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
BioDrugs Open Access 13 October 2023
-
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
BioDrugs Open Access 05 August 2023
-
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
BioDrugs Open Access 31 January 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Chirino, A.J & Mire-Sluis, A. Nat. Biotechnol. 22, 1383–1391 (2004).
Egrie, J.C., Dwyer, E., Browne, J.K., Hitz, A. & Lykos, M.A. Exp. Hematol. 31, 290–299 (2003).
Egrie, J.C. & Browne, J.K. Br. J. Cancer 84, 3–10 (2001).
European Public Assessment Report Variation, Aranesp-H-332-X-42 (2008) http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000332/human_med_000651.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124#
Glennie, M.J., French, R.R., Cragg, M.S. & Taylor R.P. Mol. Immunol. 44, 3823–3837 (2007).
Reslan, L., Dalle, S. & Dumontet, C. MAbs 1, 222–229 (2009).
Dick, L.W., Kim, C., Qiu, D. & Cheng, K.-C. Biotechnol. Bioeng. 97, 544–553 (2007).
Antes, B. et al. J. Chromatogr. B 852, 250–256 (2007).
Shields, R.L. et al. J. Biol. Chem. 277, 26733–26740 (2002).
Tracey, D. et al. Pharmacol. Ther. 117, 244–279 (2008).
Acknowledgements
NK3.3 cell line was generated by J. Kornbluth, St. Louis University School of Medicine, and the cell line was obtained by Novartis from St. Louis University, St. Louis. We would like to thank J. Windisch, M. McCamish, C. Sonderegger, M. Lang-Salchner and A. Seidl from Sandoz Biopharmaceuticals for their thorough review and support.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors are employees of Novartis/Sandoz, which is developing, manufacturing and marketing biopharmaceuticals, including biosimilar products.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1—3, Supplementary Tables 1,2 and Supplementary Methods (PDF 439 kb)
Rights and permissions
About this article
Cite this article
Schiestl, M., Stangler, T., Torella, C. et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29, 310–312 (2011). https://doi.org/10.1038/nbt.1839
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1839
This article is cited by
-
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
BioDrugs (2023)
-
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
BioDrugs (2023)
-
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
BioDrugs (2023)
-
Antibody-dependent cellular cytotoxicity-null effector developed using mammalian and plant GlycoDelete platform
Scientific Reports (2022)
-
Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
Indian Journal of Gastroenterology (2022)